8-K: Rezolute Gains FDA Alignment for Streamlined Ersodetug Trial

Rezolute, Inc. announced FDA alignment on a significantly streamlined Phase 3 clinical development path for its ersodetug trial in tumor hyperinsulinism, expediting potential therapy availability.

Summary

• Rezolute, Inc. announced FDA alignment on a significantly streamlined Phase 3 clinical development path for its upLIFT study of ersodetug for the treatment of hypoglycemia caused by tumor hyperinsulinism (HI).
• The FDA agreed to modifications to the study design, including removing the need for a double-blind randomized placebo-controlled trial.
• The revised upLIFT study will now be a single-arm open-label trial involving as few as 16 participants.
• Topline data for the upLIFT study is expected in the second half of 2026.
• The FDA confirmed that Rezolute's pivotal sunRIZE trial in congenital HI, which is on track to report topline results in December 2025, would serve as confirmatory clinical evidence, recognizing the broad applicability of ersodetug.
• Ersodetug is a fully human monoclonal antibody designed to treat all forms of HI by binding allosterically to the insulin receptor to decrease receptor over-activation, thereby improving hypoglycemia.
• Real-world evidence from the company's Expanded Access Program for tumor HI patients has shown substantial hypoglycemia improvement, discontinuation of intravenous dextrose, discharge from inpatient care, and resumption of tumor-directed therapies.

Sentiment

Score: 9

Explanation: The FDA's alignment on a significantly streamlined Phase 3 trial design, reducing patient numbers and removing the placebo-controlled arm, is a major positive regulatory and operational development. This accelerates the path to market for ersodetug in tumor hyperinsulinism, supported by real-world evidence and the ongoing congenital HI trial. The company's strong cash position further enhances confidence.

Positives

• FDA alignment on a significantly streamlined Phase 3 clinical development path for ersodetug in tumor HI.
• Removal of the requirement to conduct a double-blind randomized placebo-controlled trial for the upLIFT study.
• Reduced patient count for the upLIFT study to as few as 16 participants, focusing on a single-arm open-label design.
• Expedited development timeline, with topline data for upLIFT now expected in the second half of 2026.
• FDA recognition of the sunRIZE trial in congenital HI as confirmatory clinical evidence, demonstrating ersodetug's broad applicability across multiple forms of HI.
• Favorable outcomes observed in over 10 patients with tumor HI under the Expanded Access Program, showing real-world benefit.
• Ersodetug's novel mechanism of action, acting downstream from the pancreas, offers potential universal effectiveness at treating hypoglycemia due to any congenital or acquired form of HI.
• Strong cash position of $180 million providing runway to mid-2027.
• Ersodetug has received Breakthrough Therapy Designation (FDA), priority medicines (PRIME) designation (EMA), Innovation Passport designation (U.K. ILAP), and Orphan Drug Designation in the US and EU for congenital HI.
• Ersodetug has received Orphan Drug Designation for the treatment of hypoglycemia due to tumor HI.

Risks

• Forward-looking statements are based on certain assumptions, and actual results may differ materially from anticipated results.
• Readers are cautioned not to place undue reliance on forward-looking statements.
• Important factors that may cause differences include any other factors discussed in the company's SEC filings, including the Risk Factors contained in the company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Future Outlook

The company anticipates topline data for the sunRIZE trial in congenital HI in December 2025 and for the upLIFT study in tumor HI in the second half of 2026. They believe ersodetug has the potential to be universally effective at treating hypoglycemia due to any congenital or acquired form of HI and are expediting development with the goal of making this therapy available as efficiently as possible.

Management Comments

• "We are absolutely delighted with this regulatory outcome. The FDA’s staff and leadership have been very vocal about the desire to responsibly simplify clinical development for rare diseases, particularly when there is real-world evidence of benefit combined with mechanistic plausibility. We believe that the alignment we have achieved with the agency exemplifies this innovative approach and is substantially based upon the favorable outcomes that we have observed over the last two years treating more than 10 patients with tumor HI under our Expanded Access Program." Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute.
• "This revised and simplified plan for the upLIFT study and approval pathway marks an important development for us as well as the community of healthcare providers, patients, and families living with serious hypoglycemia caused by tumor HI. By focusing on an open-label study in upLIFT, while building upon the robust clinical foundation established in the congenital HI indication, we are expediting development with the goal of making this therapy available as efficiently as possible." Brian Roberts, M.D., Chief Medical Officer at Rezolute.

Industry Context

This announcement reflects a broader trend in rare disease drug development where regulatory bodies like the FDA are increasingly open to streamlined clinical trial designs, especially when supported by strong mechanistic plausibility and real-world evidence. This approach aims to accelerate the availability of therapies for conditions with significant unmet medical needs, such as hyperinsulinism. Ersodetug's potential universal effectiveness across HI forms positions it uniquely against existing and developing therapies which often target specific HI types or have significant limitations.

Comparison to Industry Standards

• Ersodetug (Rezolute) is a fully human monoclonal antibody with a novel mechanism acting downstream from the pancreas, designed to treat all forms of HI.
• Dasiglucagon (Zealand) is a glucagon analogue in Phase 3 for congenital HI, but its utility in chronic use is unproven, it may need combination with other therapies, and its mechanism of action is suited to post-bariatric hypoglycemia (PBH) with no plans to pursue congenital HI.
• Avexitide (Amylyx) is a GLP-1 receptor antagonist in Phase 3 for PBH, with similar drawbacks to dasiglucagon and is earlier in development.
• HM-15136 (Hanmi) is a glucagon analogue in Phase 2 for congenital HI, administered via SC injection once weekly.
• Diazoxide (DZ) is the first-line and only approved medication for hypoglycemia caused by HI, but 60% of patients do not respond, and it has frequent and serious adverse reactions including volume overload, heart failure, pulmonary hypertension, increased body hair, loss of appetite, and swelling.
• Somatostatin analogs (SSAs) are used off-label with limited success and may worsen hypoglycemia in tumor HI.
• Pancreatectomy is an invasive option for DZ non-responsive patients, often requiring adjuvant medications and leading to insulin-dependent diabetes.
• Ersodetug's real-world benefit in Expanded Access Program patients, including discontinuation of IV dextrose and hospital discharge, demonstrates a significant improvement over current suboptimal treatment options for severe refractory hypoglycemia in tumor HI.

Stakeholder Impact

• Shareholders: Positive impact due to accelerated development timeline, reduced trial costs/complexity, and increased likelihood of market entry for ersodetug, potentially leading to higher valuation.
• Patients (Tumor HI): Significant positive impact as a potentially effective therapy for severe hypoglycemia caused by tumor HI could become available sooner, addressing a high unmet medical need with limited current treatment options.
• Healthcare Providers: Provides a new, potentially more effective treatment option for managing severe hypoglycemia in tumor HI patients, potentially reducing hospitalizations and improving patient outcomes.

Next Steps

• Continue enrolling patients in the upLIFT study in the U.S. and Europe.
• Report topline results for the sunRIZE trial in congenital HI in December 2025.
• Report topline data for the upLIFT study in tumor HI in the second half of 2026.

Key Dates

Recommendation

The FDA's decision to streamline the Phase 3 trial for ersodetug in tumor hyperinsulinism is a highly significant de-risking event. It substantially reduces the time, cost, and complexity of the clinical development pathway, accelerating the potential market entry for a drug addressing a high unmet medical need. The FDA's acceptance of a single-arm, open-label study with a smaller patient cohort, coupled with the sunRIZE trial as confirmatory evidence, demonstrates strong regulatory confidence in ersodetug's potential. This positive regulatory outcome, combined with compelling real-world evidence and a solid cash runway, significantly enhances the company's prospects and warrants a "strong buy" recommendation for long-term investors.

Keywords

Rezolute, RZLT, Ersodetug, Hyperinsulinism, Tumor HI, Congenital HI, Hypoglycemia, Phase 3 Trial, FDA, Clinical Development, Rare Disease, Insulinoma, NICT, Monoclonal Antibody, Biopharmaceutical